Go Pro

Extendicare (TSE:EXE) Stock Price Passes Above 200 Day Moving Average - Time to Sell?

Extendicare logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Extendicare shares moved above their 200-day moving average of C$30.82, reaching C$31.02 before last trading at C$30.36 on notable volume.
  • Analysts remain broadly bullish: the stock has an average “Buy” rating, with eight positive ratings and a consensus price target of C$37.00. Several firms recently raised their targets, including Canaccord Genuity to C$44.00.
  • Extendicare reported quarterly EPS of C$0.32 on revenue of C$611.04 million and recently paid a monthly dividend of C$0.0441 per share, implying an annualized yield of about 1.7%.
  • MarketBeat previews top five stocks to own in September.

Extendicare Inc. (TSE:EXE - Get Free Report) crossed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of C$30.82 and traded as high as C$31.02. Extendicare shares last traded at C$30.36, with a volume of 1,282,777 shares changing hands.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on the company. Canaccord Genuity Group boosted their target price on Extendicare from C$37.00 to C$44.00 and gave the stock a "buy" rating in a research report on Monday, August 10th. National Bank Financial increased their price target on shares of Extendicare from C$34.00 to C$40.00 and gave the company an "outperform" rating in a research report on Wednesday, May 27th. TD lifted their price target on shares of Extendicare from C$32.00 to C$39.00 and gave the stock a "buy" rating in a research note on Monday, May 11th. Desjardins lowered their price objective on shares of Extendicare from C$40.00 to C$39.00 and set a "buy" rating for the company in a report on Monday, August 10th. Finally, Royal Bank Of Canada upped their price objective on shares of Extendicare from C$38.00 to C$39.00 and gave the company an "outperform" rating in a research note on Friday, August 14th. One investment analyst has rated the stock with a Strong Buy rating and seven have issued a Buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Buy" and a consensus price target of C$37.00.

Check Out Our Latest Stock Analysis on EXE

Extendicare Price Performance

The business's 50-day simple moving average is C$35.12 and its 200-day simple moving average is C$30.82. The stock has a market cap of C$2.89 billion, a PE ratio of 23.25 and a beta of 1.59. The company has a quick ratio of 0.98, a current ratio of 0.75 and a debt-to-equity ratio of 159.54.

Extendicare (TSE:EXE - Get Free Report) last posted its earnings results on Thursday, August 6th. The company reported C$0.32 earnings per share for the quarter. The company had revenue of C$611.04 million during the quarter. Extendicare had a net margin of 6.13% and a return on equity of 36.33%. On average, research analysts expect that Extendicare Inc. will post 0.6134729 EPS for the current fiscal year.

Extendicare Announces Dividend

The firm also recently declared a monthly dividend, which was paid on Monday, August 17th. Shareholders of record on Monday, August 17th were given a dividend of $0.0441 per share. The ex-dividend date of this dividend was Friday, July 31st. This represents a c) dividend on an annualized basis and a yield of 1.7%. Extendicare's dividend payout ratio is presently 39.23%.

Extendicare Company Profile

(Get Free Report)

Extendicare Inc, operating solely in Canada, is the largest private-sector owner and operator of long-term care (LTC") homes and one of the largest private-sector providers of publicly funded home health care services.

Further Reading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Should You Invest $1,000 in Extendicare Right Now?

Before you consider Extendicare, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Extendicare wasn't on the list.

While Extendicare currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks That Will Be Magnificent in 2026 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines